Stock search

Ticker or company name

Compare stocks

Market: US

  • CICigna
  • ELVElevance Health
  • HCAHCA Healthcare

Add stock

Ticker or company

Summary

CI
Cigna
$300,16Up +1,06%
Year: Up +10%
89/100Best scoreRatio would consider buying
Open stock page
ELV
Elevance Health
$446,28Up +3,86%
Year: Up +31%
78/100Ratio would consider buying
Open stock page
HCA
HCA Healthcare
$511,78Up +2,55%
Year: Up +5%
69/100Ratio would watch
Open stock page

Verdict

CI has the best score (89). CI grows revenue the fastest. CI is the cheapest by forward P/E. ELV has the lowest debt load. HCA has the highest net margin.

Verdict by our methodology based on current metrics. Not an investment recommendation.

Traffic light — 10 checks

CheckCI7 ✓ 2 — 0 ✕ELV6 ✓ 2 — 1 ✕HCA4 ✓ 3 — 1 ✕
P/E vs its history13,118,115,4
P/E vs industry13,118,115,4
Forward P/E9,114,015,2
Revenue growth, YoY+6,8%+3,6%+5,8%
EPS growth, YoY+0,3%−4,1%+16,5%
Net margin2,3%2,5%8,6%
Net debt / EBITDA−0,6−0,8n/a—
Free cash flow$9,43 bn$6,51 bn$5,97 bn
Share count over a year−1,4%−2,7%−8,0%
Cash runwayn/anot neededn/anot neededn/anot needed

Metrics

Best WorstNo mark — in between

Metric · betterCITTMELVTTMHCATTMIndustry medianTTM
P/E TTM ↓Best: 13,1Worst: 18,115,425,1
Forward P/E ↓Best: 9,114,0Worst: 15,216,2
PEG ↓Best: 1,4Worst: 4,01,82,2
P/S TTM ↓Best: 0,30,5Worst: 1,32,2
EV/EBITDA ↓Best: 8,9Worst: 13,89,717,3
P/FCF ↓Best: 8,713,8Worst: 17,519,5

Price, %

  • CIn/a
  • ELVn/a
  • HCAn/a

Returns

Best WorstNo mark — in between

PeriodCIELVHCA
1 yearn/an/an/a
3 yearsn/an/an/a
5 yearsn/an/an/a
All timen/an/an/a

“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.

Analysts and insiders

Best WorstNo mark — in between

CIELVHCA
Share of “buy”Best: 74%68%Worst: 58%
Beat the forecastWorst: 1 of 4Best: 4 of 43 of 4
Average “surprise”Worst: +0,4%Best: +22,1%+4,1%
Insiders over 12 monthssales $66,8 msales $4,74 msales $47,5 m

Details are on each stock page.